Statins and the Risk of Cancer After Heart Transplantation

Abstract

Background— Although newer immunosuppressive agents, such as mTOR (mammalian target of rapamycin) inhibitors, have lowered the occurrence of malignancies after transplantation, cancer is still a leading cause of death late after heart transplantation. Statins may have an impact on clinical outcomes beyond their lipid-lowering effects. The aim of the present study was to delineate whether statin therapy has an impact on cancer risk and total mortality after heart transplantation. Methods and Results— A total of 255 patients who underwent heart transplantation at the University Hospital Zurich between 1985 and 2007 and survived the first year were included in the present study. The primary outcome measure was the occurrence of any malignancy; the secondary end point was overall survival. During follow-up, a malignancy was diagnosed in 108 patients (42%). The cumulative incidence of tumors 8 years after transplantation was reduced in patients receiving a statin (34% versus 13%; 95% confidence interval, 0.25–0.43 versus 0.07–0.18; P <0.003). Statin use was associated with improved cancer-free and overall survival (both P <0.0001). A Cox regression model that analyzed the time to tumor formation with or without statin therapy, adjusted for age, male sex, type of cardiomyopathy, and immunosuppressive therapy (including switch to mTOR inhibitors or tacrolimus), demonstrated a superior survival in the statin group. Statins reduced the hazard of occurrence of any malignancy by 67% (hazard ratio, 0.33; 95% confidence interval, 0.21–0.51; P <0.0001). Conclusions— Although it is not possible to adjust for all potential confounders because of the very long follow-up period, this registry suggests that statin use is associated with improved cancer-free and overall survival after cardiac transplantation. These data will need to be confirmed in a prospective trial.

Phenotype-based high-content chemical library screening identifies statins as inhibitors of in vivo lymphangiogenesis

“…Since our results indicate simvastatin as an inhibitor of pathological lymphangiogenesis, it would be of interest to investigate whether cancer patients on statin therapy might have a better prognosis due to decreased tumor lymphangiogenesis and metastasis (3,6). Indeed, a recent publication indicates that patients on statin therapy develop fewer cancers and have a better prognosis once cancers have been diagnosed (44).…”

Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future

“…Ras, Rho, Rac) involved in the regulation of cellular processes including differentiation and apoptosis. These processes are germane to PAH (Connolly & Aaronson, 2011;Oka, Fagan, Jones, & McMurtry, 2008) and to cancer, where statins have been reported to reduce tumour growth and metastasis in patients following cardiac transplantation (Fröhlich et al, 2012). Prenylation of Rho proteins is essential for proper membrane localization, and appears to be required for most, but not all, known Rho functions.…”

Impact of Statin Use After Heart Transplantation

“…There was no change in summary effect size with omitting 1 study at a time or fixedeffects model. The outcomes from studies by Fröhlich et al 9 (5/151) and Grigioni et al 20 (6/186) were not included in the pooled analysis because these 2 studies reported the rates of myopathy only in heart transplant recipients undergoing statin therapy.…”